| Senast Betalt | Daglig förändring |
|---|---|
| 26.35 |
| AKTIE | Valuta | Omsättning | % | +/- | Köp | Sälj | Högst | Lägst | Datum |
|---|---|---|---|---|---|---|---|---|---|
| Diamyd Medical B | SEK | 26.15 | 26.05 | 2021-02-25 |
| Namn | Värde |
|---|---|
| Antal Aktier | 66613573 |
| Börsvärde | 1755267648.55 |
| Genomsnittlig dagsomsät. | |
| VD | Ulf Hannelius |
| Styrelseordf. | Erik Nerpin |
| Namn | Värde |
|---|---|
| Volatitet 30 dagar | 38.01% |
| Volatitet 200 dagar | 90.82% |
| Utdelning Senaste årsredovisningen |
|
| Direktavkastning |
Diamyd Medical is a diabetes company headquartered in Stockholm, Sweden. The Company develops the diabetes vaccine Diamyd® with the active ingredient GAD, which has the potential to become a key piece of the puzzle of a future solution to prevent, treat or cure type 1 diabetes and other forms of diabetes. Diamyd Medical has independently pursued the development of the diabetes vaccine Diamyd® to global Phase III trials, leading to one of Sweden’s largest biotech agreements ever.
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Nettoomsättning | 0.34 | 1.57 | 0.73 |
| Bruttoreslutat | 30.49 | -20.72 | -28.30 |
| Ebitda | 9.89 | -36.43 | -43.91 |
| Ebit | 9.74 | -36.57 | -44.04 |
| Resultat före skatt | 9.71 | -36.61 | -43.95 |
| Nettoresultat | 9.71 | -36.61 | -43.95 |
| EPS (SEK) | 0.14 | -0.53 | -0.78 |
| DPS (SEK) |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Omsättningstillväxt Å/Å | -78.25% | 115.98% | -21.26% |
| Bruttomarginal | 8940.76% | -1321.56% | -2854.27% |
| EBITDA-marginal | 2899.71% | -2323.28% | -5017.77% |
| EBIT-marginal | 2856.01% | -2332.21% | -5037.05% |
| Nettomarginal | 2847.21% | -2334.82% | -5042.7% |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Likvida medel | 58.37 | 36.70 | 14.08 |
| S:a omsättningstillgångar | 72.39 | 61.88 | 47.19 |
| S:a tillgångar | 89.76 | 74.20 | 54.98 |
| Eget kapital | 72.49 | 62.78 | 43.01 |
| S:a skulder | 17.27 | 11.42 | 11.97 |
| Nettoskuld | -67.59 | -55.94 | -43.34 |
